Dokkyo Medical University Repository / 獨協医科大学リポジトリ
Not a member yet
2844 research outputs found
Sort by
Prevalence of Asthma, Allergic Rhinitis and Atopic Dermatitis among 6-7 and 13-14-year-old Children in Oyama and Tochigi Cities, Japan
Get PDFBackground: Past several decades, the escalation in the incidence of asthma, allergic rhinitis, and atopic dermatitis has manifested as a global health concern, affecting approximately 20% of the world's population.
Objective: Assessing the prevalence of asthma, allergic rhinitis, and atopic dermatitis in elementary grade 1 (6-7 years old) and junior high grade 1 and 2 (13-14 years old) students in Oyama and Tochigi cities, Japan.
Methods: A letter was sent to parents informing them about an opt-in online survey concerning children's allergies along with a weblink and a QR code. A video explaining the survey process and informed parents that their replies could not be retracted. Parents who had watched the explanation video and answered yes to participating were considered to have provided consent for the survey.
Results: We received 431 (16.5%) survey responses as well as 346 survey replies (6.3%) from the parents of grade 1 elementary and grade1-2 junior high school students. Prevalence of symptoms in past 12 months was: wheezing 10.7% and 3.2%, rhinitis 62.2% and 66.5%, rhinoconjunctivitis 33.9% and 45.7%, itchy rash in typical sites for atopic eczema 19.3% and 12.7% for 6-7 years old and 13-14 years old respectively.
Conclusions: There was an increase in incidence experienced by children for asthma and allergic rhinitis compared to a study conducted in similar locale. Two thirds of children have experienced allergic rhinitis. On the other hand, improvement in management and treatment of asthma may have led to a decrease in prevalence of wheezing in past 12 months.journal articl
Efficacy of Second-line Cabozantinib after Immune Checkpoint Inhibitor Therapy for Clear Cell Renal Cell Carcinoma with Tumor Thrombus
Get PDFSurgical resection greatly benefits patients with renal cell carcinoma (RCC). However, patients with locally advanced RCC, including tumor thrombus and adjacent organ involvement, are at risk for perioperative complications and perioperative death. Therefore, in some cases, a multimodal approach with systemic therapy should be planned before radical surgery. A 65-year-old female patient with unresectable locally advanced left clear cell carcinoma (ccRCC) with tumor thrombus, who was considered difficult to undergo radical recection, treated with systemic therapy. The tumor responded well to second-line cabozantinib treatment after combination immunotherapy and was completely resected after surgery. This case demonstrates the efficacy of cabozantinib after immune checkpoint inhibition for locally advanced ccRCC and the importance of multimodal therapy in ccRCC.journal articl
Progress of Therapeutic Antibodies in the Treatment of Patients with Multiple Myeloma and Possible Impacts of Antibodies on the Evaluation of Response to the Treatment
Get PDFMultiple myeloma (MM) is an incurable hematological malignancy. Introduction of autologous stem cell transplantation, as well as proteasome inhibitors and immunomodulatory drugs (IMiDs) has improved the treatment results. However, many patients develop resistance to existing therapies, and novel treatment strategies for these patients must be established. Therapeutic antibodies including daratumumab or isatuximab targeting CD38 and elotuzumab targeting SLAMF7 have been introduced in the clinic as immunotherapies for MM. These antibodies exert cytotoxic effects on myeloma cells through the activation of effector cells such as natural killer cells and induction of phagocytosis by macrophages. The recent studies suggest the possibility of therapeutic antibodies to bring about influence on testing in treatment of MM. CD38 is one of the antigens used for detection of myeloma cells in flowcytometry. The use of daratumumab is supposed to downregulate CD38 expression in myeloma cells. Thus, daratumumab treatment may affect the evaluation of minimal residual disease (MRD) by flow cytometry. Immunofixation electrophoresis (IFE) to detect monoclonal protein is essential for evaluation of response to treatment. Both daratumumab and elotuzumab are derived from human IgG-k and their administration may affect the evaluation of immunofixation electrophoresis if the tumor-derived M protein belongs to the same IgG-k subclass. To overcome the influence of therapeutic antibodies on testing, a method for detecting MRD using different antibodies from conventional ones and daratumumab-specific immunofixation electrophoresis reflex assay (DIRA) for IFE have been introduced. In this review, progress of therapeutic antibodies and possible impacts of these antibodies on the evaluation of response to the treatment will be discussed.journal articl
Using a survey, analyzing the current situation of Allergic March in elementary and junior high school students of Oyama and Tochigi cities, Japan
Get PDF獨協医科大学博士（医学）令和5年度doctoral thesi
Effects of pemafibrate on primary biliary cholangitis with dyslipidemia
Get PDF獨協医科大学博士（医学）令和5年度doctoral thesi